Win the Patent Cliff: The 30-Month CDMO Playbook
The pharmaceutical sector faces a revenue contraction of $236 billion through 2030 as blockbuster patents expire. This contraction is a […]
Win the Patent Cliff: The 30-Month CDMO Playbook Read Post »
Defend the Moat: Extending Pharma Riches with Digital Health
The patent cliff is not a metaphor. It is a calendar event. A specific date — often visible years in
Defend the Moat: Extending Pharma Riches with Digital Health Read Post »
Germany’s Pharmaceutical Renaissance: Navigating the Future of Drug Development in Europe’s Powerhouse
Introduction: Why Germany Matters More Than Ever For years, the narrative surrounding Germany was one of caution. A powerful but
Double Specialty Pharmacy Margins on Generic Day One
The specialty pharmaceutical market is undergoing a structural realignment as high-value biologics and small molecules face their first wave of
Double Specialty Pharmacy Margins on Generic Day One Read Post »
Stop Patenting the Goal: Why Specificity Is the Only Shield in Biologics
The Patent Strategy That Keeps Failing Biologic drug developers have spent decades trying to own entire therapeutic concepts. Claim the
Stop Patenting the Goal: Why Specificity Is the Only Shield in Biologics Read Post »
The Billion-Dollar Equation: How to win the five-year fight for patent exclusivity
Why Five Years Is the Only Number That Matters in Pharma When Pfizer’s patent on Lipitor expired in November 2011,
The Billion-Dollar Equation: How to win the five-year fight for patent exclusivity Read Post »
Building the Unbreakable Thicket: How to Defeat Generic Entry Without Relying on Your API Patent
The Problem With Betting Everything on One Patent Every pharmaceutical brand team eventually confronts the same uncomfortable math. The active
Beyond the Drug Patent Cliff: How Procurement Can Drive Immediate Savings with Generics and Biosimilars
The global biopharmaceutical industry is approaching a critical juncture as it faces a massive wave of patent expirations for some
The Patent is the Supply Chain: A Guide to Building Unbreakable Pharmaceutical Resilience
The Efficiency Trap: Why Lean Supply Chains Broke in 2024 The global pharmaceutical landscape is currently navigating a period of
